ClinicalTrials HQ

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Active, not recruiting · NCT04551131 · Registry updated 2026-04-24
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic LymphohistiocytosisDisease Attributes, Hemic and Lymphatic Diseases, Lymphohistiocytosis, Hemophagocytic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, histiocytosis, lymphatic system disorder, non-Langerhans cell histiocytosisActive, not recruitingPhase 1 / Phase 22026-04-24NCT04551131

4 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Cures Within Reach9
Incyte Corporation153
North American Consortium for Histiocytosis4
St. Jude Children's Research Hospital169

13 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Children'S Hospital of Orange CountyOrangeUnited States128
Children's Hospital of PhiladelphiaPhiladelphiaUnited States434
Children's National Medical CenterWashington D.C.United States177
Children's Wisconsin/Medical College of WisconsinMilwaukeeUnited States3
Cohen Children's Medical CenterNew Hyde ParkUnited States16
Dana-Farber Cancer InstituteBostonUnited States626
John Hopkins UniversityBaltimoreUnited States14
Levine Children's HospitalCharlotteUnited States10
Phoenix Children's HospitalPhoenixUnited States95
St. Jude Children's Research HospitalMemphisUnited States194
Texas Children's HospitalHoustonUnited States187
University of California San FranciscoSan FranciscoUnited States80
University of Texas Southwestern Medical CenterDallasUnited States18